. "3"^^ . "6" . "1"^^ . . "Widimsk\u00FD, Ji\u0159\u00ED" . "Probl\u00E9my s nov\u00FDmi a nov\u011Bj\u0161\u00EDmi hypolipidemiky"@cs . "1"^^ . "hypolipidaemica; problems"@en . . "Cholesteryl ester transfer protein (CETP) inhibitor torcetrapib zvy\u0161uje HDL-cholesterol o 50-60%. Studie ILLUSTRATE v\u0161ak nenalezla ovlivn\u011Bn\u00ED koron\u00E1rn\u00ED ateroskler\u00F3zy studov\u00E1n\u00ED intrakoron\u00E1rn\u00EDm ultrazvukem. Mortalitn\u00ED studie ILLUMINATE musela b\u00FDt dokonce p\u0159ed\u010Dasn\u011B p\u0159eru\u0161ena, proto\u017Ee kombinace atorvastatin + torcetrapib vedla ke zv\u00FD\u0161en\u00ED mortality oproti kombinaci atorvastatin ; placebo. Vysv\u011Btlen\u00ED t\u011Bchto p\u0159ekvapiv\u00FDch n\u00E1lez\u016F nen\u00ED jasn\u00E9, ale ur\u010Ditou \u00FAlohu mohlo sehr\u00E1t zv\u00FD\u0161en\u00ED aldosteronu pozorovan\u00E9 po torcetrapibu." . "Probl\u00E9my s nov\u00FDmi a nov\u011Bj\u0161\u00EDmi hypolipidemiky" . . "CZ - \u010Cesk\u00E1 republika" . "0010-8650" . . "Cor et Vasa" . . "50" . "Cholesteryl ester transfer protein (CETP) inhibitor torcetrapib increases hDL-cholesterol by 50-60%. The ILLUSTRATE trial did not find an effect of this new drug on coronary atherosclerosis studied by intracoronary ultrasound. The ILLUMINATE trial had to be stopped because the combination of atorvastatin + torcetrapib was accompanied by an increased mortality when compared to the combination of atorvaststin and a placebo. The proper explanation of these suprising data is lacking, but an increase in aldosteron could play a role."@en . "Probl\u00E9my s nov\u00FDmi a nov\u011Bj\u0161\u00EDmi hypolipidemiky" . "Cholesteryl ester transfer protein (CETP) inhibitor torcetrapib zvy\u0161uje HDL-cholesterol o 50-60%. Studie ILLUSTRATE v\u0161ak nenalezla ovlivn\u011Bn\u00ED koron\u00E1rn\u00ED ateroskler\u00F3zy studov\u00E1n\u00ED intrakoron\u00E1rn\u00EDm ultrazvukem. Mortalitn\u00ED studie ILLUMINATE musela b\u00FDt dokonce p\u0159ed\u010Dasn\u011B p\u0159eru\u0161ena, proto\u017Ee kombinace atorvastatin + torcetrapib vedla ke zv\u00FD\u0161en\u00ED mortality oproti kombinaci atorvastatin ; placebo. Vysv\u011Btlen\u00ED t\u011Bchto p\u0159ekvapiv\u00FDch n\u00E1lez\u016F nen\u00ED jasn\u00E9, ale ur\u010Ditou \u00FAlohu mohlo sehr\u00E1t zv\u00FD\u0161en\u00ED aldosteronu pozorovan\u00E9 po torcetrapibu."@cs . "RIV/00023001:_____/08:00001780!RIV09-MZ0-00023001" . . . "Probl\u00E9my s nov\u00FDmi a nov\u011Bj\u0161\u00EDmi hypolipidemiky"@cs . "Problems with new hypolipidemic drugs"@en . . . "N" . . "RIV/00023001:_____/08:00001780" . . . "[C93061633AC0]" . "Problems with new hypolipidemic drugs"@en . "389937" .